Corporate Profile
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. In a Phase 2 study in patients with myasthenia gravis, Descartes-08 was observed to be safe and well-tolerated, and to induce deep and durable responses.
Minimum 15 minutes delayed. Source: LSEG
